Drugs / Macrin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04843891 | Sep 2021 → Apr 2023 | cancer, cardiovascular disorder, sarcoidosis | Ralph Weissleder, MD | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Macrin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04843891 ↗ |
| Modality | Diagnostic / imaging agent | “The purpose of this first-in-human study was to evaluate the biodistribution, dosimetry, and safety of 64Cu-labeled Macrin and to explore its potential for imaging inflammatory...” PMID 41469153 ↗ Mar 2026 |